SCHEDULE: CalciMedica Stakeholders Adjust Holdings

Valence Investments and key individuals report changes in beneficial ownership of CalciMedica, Inc. common stock, including participation in a recent public offering.

Summary

• This filing is an amendment to a Schedule 13D, reporting changes in beneficial ownership of CalciMedica, Inc. common stock.
• Valence Investments SPV IV, LLC now beneficially owns 356,989 shares (1.2%).
• Valence Investments SPV V, LLC now beneficially owns 86,098 shares (0.3%), including shares and warrants acquired via a Merger Agreement.
• Valence Investments SPV VI, LLC now beneficially owns 316,109 shares (1.0%).
• Eric W. Roberts beneficially owns 1,965,916 shares (6.4%), including directly held shares, IRA holdings, options, and warrants, as well as shares held by Valence entities.
• A. Rachel Leheny beneficially owns 1,926,347 shares (6.3%), including directly held shares, trust holdings, spouse's holdings, options, and warrants, as well as shares held by Valence entities.
• Since the last filing on November 6, 2024, Eric Roberts and Rachel Leheny have made open-market purchases using personal funds.
• On June 23, 2026, CalciMedica entered into a Securities Purchase Agreement for a public offering of 18,673,429 Units at $0.8033 per Unit, with the offering closing on June 25, 2026.
• Eric Roberts and Rachel Leheny each purchased 186,729 Units in this offering using personal funds.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, primarily reporting changes in ownership and participation in a capital raise without explicit commentary on performance or future outlook.

Positives

• Eric Roberts and Rachel Leheny participated in a recent public offering, acquiring a significant number of units.
• The company successfully closed a public offering of units on June 25, 2026, indicating continued investor interest.
• Key individuals (Roberts and Leheny) are actively investing personal funds into the company's stock through open-market purchases and the recent offering.

Negatives

• The price per unit in the recent public offering was $0.8033, which may indicate a lower valuation compared to previous trading prices.
• The aggregate beneficial ownership reported by Valence entities and individuals, while significant, represents a minority stake in the company.

Risks

• The filing does not explicitly detail new risks, but the participation in a public offering at $0.8033 per unit could imply underlying challenges or a need for capital that might affect future share price.
• The concentration of ownership among a few reporting persons could influence corporate governance and strategic decisions.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from management regarding future financial performance or strategic direction. The primary focus is on reporting changes in beneficial ownership and participation in a recent public offering.

Management Comments

• Mr. Roberts and Ms. Leheny have made purchases of Common Stock in open market transactions using their personal funds since November 6, 2024.
• Mr. Roberts and Ms. Leheny purchased Units in the public offering using personal funds.

Industry Context

StockSavvy.ai notes that Schedule 13D filings are critical for tracking significant changes in beneficial ownership, especially for companies in dynamic sectors like biotechnology or specialized technology where key investors and management often hold substantial stakes. The participation in a public offering at a specific price point provides a market valuation benchmark.

Stakeholder Impact

• Shareholders: The public offering at $0.8033 per unit may influence share price and dilution. The active participation of key individuals in purchasing units could be seen as a positive signal of confidence.
• Management/Insiders: Eric Roberts and Rachel Leheny have increased their direct and indirect holdings, signaling continued commitment.
• Investors: The filing provides transparency on significant ownership changes and capital raising activities.

Next Steps

• Continued monitoring of beneficial ownership changes.
• Analysis of the impact of the recent public offering on the company's capital structure and share price.

Key Dates

Keywords

Schedule 13D, CalciMedica, Valence Investments, Eric Roberts, Rachel Leheny, Beneficial Ownership, Securities Purchase Agreement, Public Offering, Common Stock, Warrants, Options